Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Cuts Target Price to $30

Futu NewsJan 27 21:31 · Ratings

CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Are up 7.1% This Past Week, but Still in the Red Over the Last Year

Simply Wall StJan 27 18:15

Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)

TipRanksJan 27 18:15 · Ratings

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Yahoo FinanceJan 25 07:00

Trump's HHS Pick RFK Jr. to Face Key Senate Hearings Next Week

Seeking AlphaJan 23 23:34

Bargain Basement CRISPR Therapeutics Becomes Takeover Target

TipRanksJan 23 16:57